UCB Trading (Shanghai) Co., Ltd.

To evaluate whether DZP as adjunctive treatment to standard treatment can improve clinically relevant symptoms of moderate to severe disease activity in the long term To evaluate whether DZP as adjunctive treatment to standard treatment can quickly improve clinically relevant symptoms of moderate to severe disease activity To evaluate whether DZP as adjunctive treatment to standard treatment can control disease activity in the long term To evaluate whether DZP as adjunctive treatment to standard treatment can achieve and maintain treatment goals: low disease activity can be maintained for a long time using low/acceptable doses of corticosteroids To evaluate whether DZP as adjunctive treatment to standard treatment can improve disease activity (determined by a numerical disease status rating scale commonly used in clinical practice) To evaluate whether DZP as adjunctive treatment to standard treatment can achieve improvements in the scores of each component of the composite primary endpoint To evaluate whether DZP as adjunctive treatment to standard treatment can achieve surrogate endpoint responses To evaluate whether DZP as adjunctive treatment to standard treatment can achieve endpoints that support other key secondary endpoints To evaluate the safety and tolerability of DZP as adjunctive treatment to standard treatment

Primary objective: To compare the efficacy of Bimekizumab administered subcutaneously for 16 weeks with placebo in the treatment of moderate to severe plaque PSO study subjects. Secondary objectives: To evaluate the efficacy of Bimekizumab compared with placebo at 4 weeks: achieving PASI75 response; To evaluate the efficacy of Bimekizumab compared with placebo at 16 weeks: achieving complete clearance (PASI100); To evaluate the effect of Bimekizumab compared with placebo at 16 weeks on pruritus, pain and scaling as assessed by PSD (P-SIM) response; To evaluate the safety of Bimekizumab during the 16-week treatment period.

To evaluate the long-term safety and tolerability of Staccato alprazolam To evaluate the probability of success of repeat treatment with Staccato alprazolam (for treatment of seizures occurring within the first 6 months [up to 10 seizures treated]) To evaluate the probability of success of repeat treatment with Staccato alprazolam without seizure recurrence within 2 hours (for treatment of seizures occurring within the first 6 months [up to 10 seizures treated]) To evaluate the long-term pulmonary safety of Staccato alprazolam